Skip to main content
OpenTrials
Completed

NCT Number: NCT00015301

Methylphenidate Raclopride Positron Emission Tomography (PET) Test - 11

The purpose of this study is to evaluate PET methodology to study in vivo synaptic dopamine release.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cocaine-Related Disorders Chemically-Induced Disorders Mental Disorders Substance-Related Disorders

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

New York MDRU

New York, 10010, United States

About this study

The objective of this study is to evaluate PET methodology to study in vivo synaptic dopamine release.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Healthy normals

Exclusion criteria

History of head trauma or loss of consciousness. Significant medical history. History of seizures.

Treatment and study plan

Methylphenidate

Drug

Primary outcomes

  1. Dopamine receptor availability

Sponsors and collaborators

Lead sponsor

National Institute on Drug Abuse (NIDA)

Nih

Collaborators

  • New York MDRU

Registry information

Official study title

Methylphenidate Raclopride PET Test

Important dates

Study start
2003
Primary completion
2005
Study completion
2005
First posted
Apr 18, 2001
Registry last updated
Feb 24, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.